Accessed 20 Apr 2017 Stanley CA, Bennett MJ, Longo N (2014) Plasma membrane carnitine transporter defect, In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G (eds) The online metabolic and molecular bases of inherited disease New York, McGraw-Hill, New York
delivery by Oct 21Shenzhen Yuhongkang Technology Company Limited5 yrsCN45% Reorder rate49 Interested customers
FOXO4-DRI acts as a competitive inhibitor of this interaction binding directly to the transactivation domain 2 (TAD2) of p53, displacing FOXO4, and allowing phosphorylated p53 to be exported from the nucleus and directed to mitochondria, where it activates BAX, triggers caspase-3 cleavage (via the p53/BCL-2/Caspase-3 signalling pathway), and drives cell-intrinsic apoptosis
Weve seen researchers misplace a decimal and end up with a solution thats ten times too strong or too weak